StocksMedium•6 October 2026•
1 min read
Enliven Therapeutics Reaches FDA Alignment on Phase 3 Trial for Relcobatinib
Key Facts
1Enliven Therapeutics reached alignment with the FDA on the final design of the ENABLE-2 pivotal Phase 3 trial.
2The trial evaluates relcobatinib (ELVN-001) in patients with previously treated chronic myeloid leukemia (CML).
3The company remains on track to initiate the ENABLE-2 trial before the end of 2026.
Enliven Therapeutics reached alignment with the FDA on the final design of the ENABLE-2 pivotal Phase 3 trial. The company said in a statement via PR Newswire that the clinical trial evaluates relcobatinib (ELVN-001) in patients with previously treated chronic myeloid leukemia (CML). Enliven remains on track to initiate the ENABLE-2 trial before the end of 2026.
ELVN closed at $45.47 on October 5, 2026, having traded between a day high of $46.94 and a low of $45.23. The regulatory alignment provides a clear path for the drug's clinical development, reducing uncertainty surrounding the company's lead candidate for CML treatment.